CAM2038 are buprenorphine subcutaneous investigational new drugs in late-stage clinical development for the treatment of opioid addiction. Once-weekly and once-monthly formulations have been developed, each with multiple doses, to allow individualized treatment of patients with opioid use disorder as part of a comprehensive treatment plan to include counseling and psychosocial support.
The CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery and medication adherence to minimize the risks of diversion, abuse, misuse, and accidental exposure by children.
Design attributes of CAM2038 include small dose volumes of maximum about 0.6 mL (for the highest weekly dose) in prefilled syringes with a thin 23 gauge injection needle and administered subcutaneously, intended to minimize discomfort for patients. CAM2038 is stored at room temperature and is provided ready for use in a prefilled syringe.
A risperidone-containing implant, BB0817 has the potential for a long-term treatment duration for patients with schizophrenia. BB0817 is currently in Phase 3 development.
A subcutaneous injectable formulation of buprenorphine and granisetron that is being investigated in patients with post-surgical pain and to reduce nausea and vomiting. BB0417 is currently in Phase 1 development.
A tizanidine-containing implant under investigation for the potential long-term treatment of spasticity. BB1216 is currently in animal testing of the formulation, and if this testing is successful, we expect that it will advance directly to Phase 3 development.